PC3I News
The last two decades have seen quite a bit of change around national guidelines for cervical cancer screening, with a steady shift from cytology, or Pap smears, toward an increase of human papillomavirus (HPV) testing, with or without cytology. With HPV testing being more sensitive, it has been positioned as the recommended and even preferred means of screening by the American Cancer Society and United States Preventive Task Force (among others). Until now, however, there has not yet been published evidence regarding public awareness of this form of testing.
In order to fill this void and examine public screening knowledge and uptake, PC3I Faculty Katharine A. Rendle and team Shannon N. Ogden, Emily A. Leskinen, Elizabeth A. Sarma, and Jocelyn V. Wainwright examined the effects of messaging and message framing on screening knowledge and intention related to HPV testing in a study published in Cancer Prevention Research.
Participants were randomly assigned to receive messages of two different types regarding cervical cancer screening. Gain-framed messages contained communications on the benefit of preventive care, while the messages with loss-framing focused on the risks of not participating in this care. Pretest and posttest measures evaluated participants’ knowledge of cervical cancer and intentions to be screened using primary HPV testing.
Across both types of message framing, posttests demonstrated a significant increase regarding participants’ aim to pursue HPV testing and participants’ perceived effectiveness of this form of testing to reduce cervical cancer mortality. These results establish messaging as a powerful tool in increasing awareness and uptake of primary HPV testing for cervical cancer screening.
The study, “Effects of Message Framing on Cervical Cancer Screening Knowledge and Intentions Related to Primary HPV Testing,” appeared in Cancer Prevention Research on April 12, 2021.
Katharine A. Rendle, PhD, MSW, MPH, is the Director of Implementation Science and an Innovation Faculty member at the Penn Center for Cancer Care Innovation, as well as the Associate Director of the Mixed-Methods Research Lab and an Assistant Professor of Family Medicine and Community Health and of Epidemiology at the Perelman School of Medicine.
Related News
PC3I News
PC3I Presents 20 First- and Senior-Authored Abstracts at ASCO 2022
06.02.2022
The ASCO Annual Meeting 2022 features 20 first- and senior-authored abstracts from Innovation Faculty, Fellows, and staff at the Penn Center for Cancer Care Innovation (PC3I).
PC3I News
PC3I Fellow Wins Conquer Cancer ASCO Young Investigator Award
05.24.2022
The Penn Center for Cancer Care Innovation is proud to announce that PC3I Fellow John Lin, MD, has won a Young Investigator Award from Conquer Cancer, the ASCO Foundation.
PC3I News
Leveraging Peer Comparison to Improve Hospice Utilization
04.04.2022
This randomized trial leverages peer comparisons to combat physician optimism bias found improved hospice utilization metrics among a group of academic oncologists.